Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antipsychotic polypharmacy.

J Ananth1, S Parameswaran, S Gunatilake

  • 1Metropolitan State Hospital, 11401 Bloomfield Avenue, Norwalk, CA 90650, USA. jananth@rei.edu

Current Pharmaceutical Design
|July 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Windswept deformity of lower limbs in a patient with end-stage renal disease and rickets.

Kidney international·2022
Same author

Biofuels and Sustainability.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

The ORNATE India Project: United Kingdom-India Research Collaboration to tackle visual impairment due to diabetic retinopathy.

Eye (London, England)·2020
Same author

Persistent Metabolic Acidosis on Regular Hemodialysis or Peritoneal Dialysis.

Indian journal of nephrology·2019
Same author

Epidemiology and Outcomes of Acute Kidney Injury in Critically Ill: Experience from a Tertiary Care Center.

Indian journal of nephrology·2019
Same author

Pseudoaneurysm of Thyrocervical Trunk Following Left Internal Jugular Vein Cannulation.

Indian journal of nephrology·2018
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Polypharmacy, using multiple drugs for one condition, is common in mental health due to various factors. More scientific data is needed to distinguish effective from ineffective polypharmacy practices.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Polypharmacy, the use of multiple medications for a single condition, is prevalent in managing chronic diseases like psychosis.
  • Several factors contribute to polypharmacy, including disease chronicity, high patient expectations, availability of new drugs, and systemic pressures on healthcare providers.

Purpose of the Study:

  • To explore the reasons behind the common practice of polypharmacy in mental health treatment.
  • To highlight the potential risks associated with polypharmacy, such as adverse effects and drug interactions.
  • To emphasize the need for scientific evidence to differentiate between beneficial and detrimental polypharmacy.

Main Methods:

  • Review of contributing factors to polypharmacy in psychiatric care.
  • Analysis of existing data on polypharmacy rates, including a 1997 study on schizophrenia treatment.

Related Experiment Videos

  • Discussion of strategies to reduce polypharmacy and their limited long-term impact.

    • Main Results:

    • Polypharmacy is driven by complex factors, including the chronic nature of mental illness and systemic pressures.
    • A significant percentage of patients with schizophrenia were treated with multiple antipsychotics.
    • Current methods to reduce polypharmacy have shown limited long-term success, and academicians often support its use.

    Conclusions:

    • The efficacy of polypharmacy in psychiatric care is not well-established, necessitating further scientific investigation.
    • Distinguishing between appropriate and inappropriate polypharmacy is crucial for patient safety and treatment optimization.
    • Physicians face ethical and legal challenges regarding polypharmacy due to a lack of clear guidelines and evidence.